| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000038465 |
| Receipt No. | R000043802 |
| Scientific Title | Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults -Placebo-controlled randomized, double-blind study- |
| Date of disclosure of the study information | 2021/03/01 |
| Last modified on | 2021/03/11 (Ver. 2) |
| Basic information | ||
| Public title | Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults
-Placebo-controlled randomized, double-blind study- |
|
| Acronym | Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults | |
| Scientific Title | Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults
-Placebo-controlled randomized, double-blind study- |
|
| Scientific Title:Acronym | Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults | |
| Region |
|
|
| Condition | |||||
| Condition | Healthy elderly adults with poor cognitive performance, MCI | ||||
| Classification by specialty |
|
||||
| Classification by malignancy | Others | ||||
| Genomic information | NO | ||||
| Objectives | |
| Narrative objectives1 | We examine the maintenance or improvement effect of cognitive function and the safety when the elderly subjects take functional food for 12 weeks. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Cognitrax |
| Key secondary outcomes | Various cognitive function tests and questionnaires, blood and urine tests |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of functional food for 12 weeks | |
| Interventions/Control_2 | Ingestion of placebo for 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Japanese men and women aged greater than or equal to 40 years, less than 80 years at the time of obtaining informed consent.
2. Subjects with MMSE score of 24 to 29 at screening. 3. Subjects who have subjective forgetfulness or have been pointed out forgetfulness by others. 4. Subjects who got adequate explanation about the purpose and details of the examination, have the capacity to consent, voluntarily participate in understanding, and agree to participate in the examination in writing. |
|||
| Key exclusion criteria | 1. Subjects who judged by a doctor as dementia.
2. Subjects who have taken or had taken drugs of dementia. 3. Subjects who regularly take drugs that may affect cognitive functions. 4. Subjects who have current medical history or past medical history of mental disorders (including depressive symptoms) or cerebrovascular diseases. 5. Subjects who regularly use supplements or health foods that may affect cognitive functions. 6. Subjects who judged inappropriate as subjects as a result of clinical examination of screening. 7. Subjects with gerontological depression scale (GDS-S-J) scores of 6 or more. 8. Subjects who have history of alcohol dependence or current medical history. 9. Subjects who consume a large amount of alcohol routinely. 10. Subjects who have serious illness or medical history such as diabetes, liver disease, kidney disease, heart disease. 11. Subjects who have medical history or history of food allergies or current medical history. 12. Subjects who have color vision disorder and can not easily hear people's talk at short distance. 13. Subjects who have problems with the functions of both hands due to injury, surgery, etc. 14. Subjects who are planning to participate and/or had participated in other clinical studies within the last one month prior to the current study. 15. Subjects who are judged as unsuitable for the current study by the investigator for other reasons. |
|||
| Target sample size | 90 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Nihonbashi Cardiology Clinic | ||||||
| Division name | Director | ||||||
| Zip code | 103-0001 | ||||||
| Address | Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo | ||||||
| TEL | 03-5641-4133 | ||||||
| yiwama@well-sleep.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | KSO Corporation | ||||||
| Division name | Sales department | ||||||
| Zip code | 105-0023 | ||||||
| Address | Shibaura OMODAKA Bldg. 7F, 1-9-7 Shibaura, Minato-ku, Tokyo | ||||||
| TEL | 03-3452-7733 | ||||||
| Homepage URL | |||||||
| yoshi@kso.co.jp | |||||||
| Sponsor | |
| Institute | KSO Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Yamada Bee Company, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Nihonbashi Cardiovascular Department Clinic Ethics Committee |
| Address | Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo |
| Tel | 03-5641-4133 |
| yiwama@well-sleep.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043802 |